Plain-English translation of NCT06440850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications called and , given before standard radioactive iodine therapy, can help people with a specific type of high-risk thyroid cancer respond better to treatment. These medications target a genetic mutation (BRAFV600E) found in some thyroid cancers. The goal is to see if this medication combination can make the cancer more responsive to radioactive iodine, which is the standard next step in treatment for many thyroid cancer patients.
Some patients with thyroid cancer don't respond well to standard radioactive iodine therapy. Doctors believe that using this medication combination beforehand might 'wake up' cancer cells and make them more sensitive to the radioactive iodine, potentially improving outcomes for people with this harder-to-treat form of thyroid cancer.
You likely qualify if…
You likely don't qualify if…
You would take the two medications by mouth for about 6 weeks, following a specific schedule. Then you would receive radioactive iodine as the standard treatment, continuing the medications for a few days after. Throughout the study, you would have regular blood tests, imaging scans (including MRI, CT or PET, and iodine scans), and ultrasounds to see how well the treatment is working. After the main treatment phase, you would return for follow-up visits every 3 months for up to a year to monitor your progress.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States